Durable remission in a patient with leptomeningeal relapse of a MYC/BCL6-positive double-hit DLBCL treated with lenalidomide monotherapy

Massimiliano Salati, Vittoria Tarantino, Antonino Maiorana, Stefania Bettelli, Stefano Luminari

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Secondary central nervous system involvement is an uncommon event that typically occurs early in the natural history of diffuse large B-cell lymphoma and presents as leptomeningeal dissemination in two-thirds of cases. The prognosis of this event is dismal, and treatment options are meagre. Although major validated risk factors for central nervous system dissemination are clinical, concomitant MYC/BCL2 rearrangements as well as MYC/BCL2 protein expression have been recently associated with an increased risk of this complication. Here we present the first case, to our knowledge, of a MYC/BCL6-positive double-hit diffuse large B-cell lymphoma relapsing in the leptomeninges that achieved an outstanding durable remission with single-agent lenalidomide following salvage chemotherapy.

Original languageEnglish
JournalHematological Oncology
DOIs
Publication statusAccepted/In press - 2016

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Proto-Oncogene Proteins c-bcl-2
Central Nervous System
Recurrence
Drug Therapy
lenalidomide
Therapeutics

Keywords

  • CNS lymphoma
  • Double-hit lymphoma
  • Lenalidomide

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Durable remission in a patient with leptomeningeal relapse of a MYC/BCL6-positive double-hit DLBCL treated with lenalidomide monotherapy. / Salati, Massimiliano; Tarantino, Vittoria; Maiorana, Antonino; Bettelli, Stefania; Luminari, Stefano.

In: Hematological Oncology, 2016.

Research output: Contribution to journalArticle

Salati, Massimiliano ; Tarantino, Vittoria ; Maiorana, Antonino ; Bettelli, Stefania ; Luminari, Stefano. / Durable remission in a patient with leptomeningeal relapse of a MYC/BCL6-positive double-hit DLBCL treated with lenalidomide monotherapy. In: Hematological Oncology. 2016.
@article{266a3f6566f1475ea43f88f77f760ab9,
title = "Durable remission in a patient with leptomeningeal relapse of a MYC/BCL6-positive double-hit DLBCL treated with lenalidomide monotherapy",
abstract = "Secondary central nervous system involvement is an uncommon event that typically occurs early in the natural history of diffuse large B-cell lymphoma and presents as leptomeningeal dissemination in two-thirds of cases. The prognosis of this event is dismal, and treatment options are meagre. Although major validated risk factors for central nervous system dissemination are clinical, concomitant MYC/BCL2 rearrangements as well as MYC/BCL2 protein expression have been recently associated with an increased risk of this complication. Here we present the first case, to our knowledge, of a MYC/BCL6-positive double-hit diffuse large B-cell lymphoma relapsing in the leptomeninges that achieved an outstanding durable remission with single-agent lenalidomide following salvage chemotherapy.",
keywords = "CNS lymphoma, Double-hit lymphoma, Lenalidomide",
author = "Massimiliano Salati and Vittoria Tarantino and Antonino Maiorana and Stefania Bettelli and Stefano Luminari",
year = "2016",
doi = "10.1002/hon.2315",
language = "English",
journal = "Hematological Oncology",
issn = "0278-0232",
publisher = "wiley",

}

TY - JOUR

T1 - Durable remission in a patient with leptomeningeal relapse of a MYC/BCL6-positive double-hit DLBCL treated with lenalidomide monotherapy

AU - Salati, Massimiliano

AU - Tarantino, Vittoria

AU - Maiorana, Antonino

AU - Bettelli, Stefania

AU - Luminari, Stefano

PY - 2016

Y1 - 2016

N2 - Secondary central nervous system involvement is an uncommon event that typically occurs early in the natural history of diffuse large B-cell lymphoma and presents as leptomeningeal dissemination in two-thirds of cases. The prognosis of this event is dismal, and treatment options are meagre. Although major validated risk factors for central nervous system dissemination are clinical, concomitant MYC/BCL2 rearrangements as well as MYC/BCL2 protein expression have been recently associated with an increased risk of this complication. Here we present the first case, to our knowledge, of a MYC/BCL6-positive double-hit diffuse large B-cell lymphoma relapsing in the leptomeninges that achieved an outstanding durable remission with single-agent lenalidomide following salvage chemotherapy.

AB - Secondary central nervous system involvement is an uncommon event that typically occurs early in the natural history of diffuse large B-cell lymphoma and presents as leptomeningeal dissemination in two-thirds of cases. The prognosis of this event is dismal, and treatment options are meagre. Although major validated risk factors for central nervous system dissemination are clinical, concomitant MYC/BCL2 rearrangements as well as MYC/BCL2 protein expression have been recently associated with an increased risk of this complication. Here we present the first case, to our knowledge, of a MYC/BCL6-positive double-hit diffuse large B-cell lymphoma relapsing in the leptomeninges that achieved an outstanding durable remission with single-agent lenalidomide following salvage chemotherapy.

KW - CNS lymphoma

KW - Double-hit lymphoma

KW - Lenalidomide

UR - http://www.scopus.com/inward/record.url?scp=84976871846&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84976871846&partnerID=8YFLogxK

U2 - 10.1002/hon.2315

DO - 10.1002/hon.2315

M3 - Article

AN - SCOPUS:84976871846

JO - Hematological Oncology

JF - Hematological Oncology

SN - 0278-0232

ER -